A licensing opportunity exists to develop a simple, single assay for blood coagulation abnormalities and potentially identify patients at risk of clinical thrombotic events. The assay would screen for the presence of anticardiolipin (ACL) and lupus anticoagulant (LA) autoantibodies.


Presently two assay systems are used in clinical practice to identify blood coagulation abnormalities. In the case of ACL, an ELISA test is directed towards binding of β2-GPI, even though ACL autoantibodies in a number of infections such as malaria, syphilis, leprosy, and tuberculosis do not bind to β2-GPI. In these instances, therefore, the ACL test is not accurate. The LA assay examines the prolongation of in-vitro clotting. Clinical testing requires both assays.

More Information and Contact Details:PDF version of Non-Confidential Disclosure Document